Introduction {#s1}
============

The phosphatase and tensin homolog gene (*PTEN*) functions as a negative repressor of the PI3K/Akt survival pathway and is one of the most frequently deleted tumor suppressor genes in human cancer ([@bib31]; [@bib30]). As a regulator of PI3K signaling, loss of *PTEN* results in over-activation of Akt, leading to unchecked cell proliferation, reduced apoptosis, and elevated tumor angiogenesis ([@bib31]; [@bib3]). In prostate cancer, decreases in PTEN protein expression, either by allelic deletion or functional loss caused by mutation and/or epigenetic modification, can lead to invasive prostate carcinoma ([@bib37]; [@bib25]). In preclinical systems, the genetic restoration of *PTEN* induces apoptosis in cancer cell lines and has a significant negative effect on tumor growth in multiple in vivo models ([@bib20]; [@bib21]; [@bib36]; [@bib7]). In contrast, clinical efforts to restore *PTEN* functionality have instead focused on targeting kinases in the PI3K pathway, including PI3K, Akt, and the mammalian target of rapamycin ([@bib16]). However, the development of PI3K targeting drugs has been complicated by the limited tolerability of current pharmacological treatments as well as tumor heterogeneity ([@bib14]; [@bib1]).

It is increasingly apparent that a complex regulatory network exists between the diverse RNA species pervasive in the human transcriptome. MicroRNAs (miRNAs) are small non-coding RNAs that bind to complementary sequences in the 3′ untranslated regions (UTR) of target messenger RNAs (mRNA), resulting in transcriptional downregulation of the target gene ([@bib28]). Meng and colleagues showed that *PTEN* was repressed by *miR-21*, one of the most frequently upregulated miRNAs in cancer, in hepatocarcinoma cells, suggesting that the oncogenic potential of *miR-21* occurs via the downregulation of *PTEN* expression ([@bib5]; [@bib23]; [@bib38]; [@bib24]; [@bib29]). Several miRNAs that target *PTEN* have since been reported ([@bib17]; [@bib39]). While miRNAs play a functional role in silencing target gene expression, it is proposed that miRNAs themselves are subject to regulation by competing endogenous RNA (ceRNA) species, including pseudogenes, long non-coding RNAs, and circular RNAs ([@bib27]; [@bib4]). In plants, for example, the non-protein coding gene *IPS1* sequesters miRNAs away from their mRNA targets, thereby leading to an accumulation of target transcripts ([@bib11]). Poliseno and colleagues proposed that pseudogenes, which are non-coding genomic DNA sequences closely related to parental genes, can modulate parental gene expression by influencing the available levels of miRNAs within a cell ([@bib26]; [@bib4]). However, the extent and manner that ceRNAs can exert a consequential effect on the repression of targets for that miRNA is currently unclear ([@bib2]). Recently, Denzler and colleagues analyzed the stoichiometric relationship of miR-122 and target sites in adult mouse liver and reported that the natural abundance of target sites exceeded miRNAs, making the ceRNA hypothesis unlikely ([@bib8]).

*PTENP1* is a pseudogene that shares close homology with *PTEN*, including the ability to bind miRNAs ([@bib12]). To determine whether *PTEN* and *PTENP1* expression levels are modulated by miRNA activity, Poliseno and colleagues first established that the *PTEN*-targeting miRNAs *miR-19b* and *miR-20a* were able to target both *PTEN* and *PTENP1* ([@bib26]). As reported in Figure 1D, overexpression of *miR-19b* and *miR-20a* in prostate cancer cells resulted in a significant decrease in *PTEN* and *PTENP1* mRNA transcription. This is supported by additional studies demonstrating that overexpression of either *miR-19b* or *miR-20a* in cancer cell lines resulted in reduced *PTEN* mRNA levels and protein expression ([@bib22]; [@bib35]; [@bib40]). The ability of *miR-19b* and *miR-20a* to target *PTEN* in prostate cancer was further confirmed by [@bib33]. These key findings established that *PTEN* and *PTENP1* are regulated by interactions with miRNA in multiple cancer cell types and will be replicated in Protocol 1.

In Figure 2F-H, Poliseno and colleagues tested the phenotypic consequences of *PTENP1* downregulation by specifically targeting *PTEN* and/or *PTENP1* expression. Downregulation of *PTENP1* in DU145 prostate cancer cells resulted in a significant decrease in both *PTEN* and *PTENP1* mRNA levels and protein expression (Figure 2G-H; [@bib26]). Furthermore, downregulation of *PTENP1* profoundly accelerated the proliferation of DU145 cells (Figure 2F), with silencing of both *PTEN* and *PTENP1* having an additive effect ([@bib26]). These experiments will be replicated in Protocols 2, 3, and 4. Recently, Tay and colleagues reported that *PTEN*-ceRNAs, including *CNOT6L* and *VAPA*, phenocopied *PTENP1* activity, as downregulation of these non-coding transcripts in prostate and colon cancer cells were also able to modulate *PTEN* expression, Akt activity, and cell growth ([@bib33]). Additionally, other *PTEN*-ceRNAs that regulate *PTEN* expression have been reported in brain, breast, and skin cancers ([@bib19]; [@bib18]; [@bib32]). Further to this, PTENP1 antisense RNA has been reported to regulate PTEN transcription and mRNA stability, suggesting a model where the PTENP1 pseudogene has biomodal functionality modulating PTEN ([@bib17a]).

As an extension of the findings reported in Figure 2 and further genomic analysis, Poliseno and colleagues demonstrated that the *PTEN* 3′ UTR regulates pseudogene expression, since overexpression of the *PTEN* 3′ UTR was found to de-repress *PTENP1* expression and inhibited DU145 proliferation (Figure 4A) ([@bib26]). These experiments will be replicated in Protocols 5 and 6. These results were also confirmed by experiments by Yu and colleagues showing that overexpression of either *PTEN* or *PTENP1* suppressed renal cancer cell proliferation ([@bib41]). Further to this, the oncosuppressive properties of overexpressing *PTENP1* 3′ UTR have been reported in various cancer cells ([@bib26]; [@bib6]; [@bib15]).

Materials and methods {#s2}
=====================

Protocol 1: Quantitative PCR after miR transfection {#s2-1}
---------------------------------------------------

This experiment utilizes quantitative RT-PCR to analyze the effect of miR-19b or miR-20a on the mRNA levels of *PTEN* and *PTENP1*. It is a replication of Figure 1D.

### Sampling {#s2-1-1}

■ Experiment to be repeated a total of six times for a minimum power of 88%.○ See 'Power calculations' section for details.■ Experiment has 5 conditions:○ Cohort 1: siGENOME non-targeting siRNA \#2 (siLUC) transfected DU145 cells.○ Cohort 2: miR-19b transfected DU145 cells.○ Cohort 3: miR-20a transfected DU145 cells.○ Cohort 4: Untransfected DU145 cells (additional negative control).○ Transfection control: siGLO RISC-free siRNA transfected DU145 cells.■ Quantitative RT-PCR performed in technical triplicate for the following genes:○ PTEN.○ PTENP1.○ *ACTIN* (internal control).○ *36B4* (additional internal control).

### Materials and reagents {#s2-1-2}

ReagentTypeManufacturerCatalog \#CommentsDU145 cellsCell lineATCCHTB-81--RPMI 1640 mediumCell cultureSigma--AldrichR8758Replaces Invitrogen brand used in original studyFetal bovine serum (FBS)Cell cultureSigma--AldrichF2442Replaces Invitrogen brand used in original studyL-glutamineCell cultureSigma--AldrichG7513Original brand not specified100× Penicillin/streptomycinCell cultureSigma--AldrichP4333Original brand not specified0.05% trypsin/0.48 mM EDTACell cultureSigma--AldrichT3924Original brand not specifiedPhosphate buffered saline (PBS), without MgCl~2~ and CaCl~2~Cell cultureSigma--AldrichD8537Original brand not specified12 well tissue culture dishesLabwareCorning3513Original brand not specifiedsiGLO RISC-free siRNANucleic acidDharmaconD-001600-01--siGENOME non-targeting siRNA \#2 (siLUC)Nucleic acidDharmaconD-001210-02--miRIDIAN microRNA hsa-miR-19b-3p (si-miR-19b)Nucleic acidDharmaconIH-300489-05-0002--miRIDIAN microRNA hsa-miR-20a-5p (si-miR20a)Nucleic acidDharmaconIH-300491-05-0002--Dharmafect 1Cell cultureDharmaconT-2001-01--*PTENP1* forward and reverse primersNucleic acidSpecific brand information will be left up to the discretion of the replicating lab and recorded later*PTEN* forward and reverse primersNucleic acid*ACTIN* forward and reverse primersNucleic acid*36B4* forward and reverse primersNucleic acidTRI reagentChemicalSigma--AldrichT9424Replaces Trizol reagent from Invitrogen1-bromo-3-chloropropaseChemicalSigma--AldrichB9673Reagent needed from TRI reagent protocolNuclease free waterChemicalSigma--AldrichW4502Reagent needed from TRI reagent protocolMicroscopeInstrumentZeiss--Original brand not specifiedAxiovisionSoftwareZeiss--Original brand not specifiedDNAse I amplification gradeChemicalSigma--AldrichAMPD1Replaces Invitrogen brand used in original studyFirst-strand cDNA synthesis kit (includes pd(N)6 random hexamers and NotI-(dT)18 primers)KitSigma--AldrichGE27-9261-01Replaces SuperScript II reverse transcriptase from Invitrogen used in original studyQuantiTect Sybr Green PCR kitKitQiagen204141--Real Time System with a C1000 Thermal CyclerInstrumentBioRadCFX 96Replaces Roche Lightcycler 2.0 used in original study

### Procedure {#s2-1-3}

#### Notes {#s2-1-3-1}

Cells will be sent for mycoplasma testing and short tandem repeat (STR) profiling.DU145 cells are grown in complete RPMI 1640 supplemented with 2 mM glutamine, 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C and 6% CO~2~.Seed 1.5 × 10^5^ DU145 cells per well in a 12-well dish. Grow overnight.Transfect with 100 nM siLuc, si-miR-19b, and si-miR-20a using 3 µl of Dharmafect 1 according to manufacturer\'s instructions. Transfect control cells with siGLO RISC-free control siRNA following manufacturer\'s instructions. Include untransfected control cells. Grow overnight.Confirm that \>90% of siGLO transfected control cells show fluorescence, indicating they were successfully transfected.a. If transfection is less than 90%, record efficiency for attempt, exclude attempt and do not continue with the rest of the procedure. Repeat procedure until \>90% efficiency is obtained.b. If modification to transfection (step 2) is needed, record and maintain modified steps for remaining replicates.24 hr after transfection, extract total RNA from cells directly on the culture dish using TRI reagent and 1-bromo-3-chloropropane according to manufacturer\'s instructions.Treat RNA with DNAse I following manufacturer\'s instructions.a. Record RNA concentration and purity (A~280~/A~260~).Reverse transcribe 1 µg RNA/sample into cDNA using first-strand cDNA synthesis kit with primers following manufacturer\'s instructions.Perform quantitative PCR reaction using the QuantiTect Sybr Green PCR kit:a. Use 2 µl of reverse transcription reaction per 20 µl real-time PCR reaction.b. Perform quantitative PCR for *PTEN*, *PTENP1*, *ACTIN*, and *36B4.*i. *PTEN* forward primer: 5′-GTTTACCGGCAGCATCAAAT-3′ii. *PTEN* reverse primer: 5′-CCCCCACTTTAGTGCACAGT-3′iii. *PTENP1* forward primer: 5′-TCAGAACATGGCATACACCAA-3′iv. *PTENP1* reverse primer: 5′-TGATGACGTCCGATTTTTCA-3′v. *ACTIN* forward primer: 5′-CATGTACGTTGCTATCCAGGC-3′vi. *ACTIN* reverse primer: 5′-CTCCTTAATGTCACGCACGAT-3′vii. *36B4* forward primer: 5′-GTGTTCGACAATGGCAGCAT-3′viii. *36B4* reverse primer: 5′-GACACCCTCCAGGAAGCGA-3′i. *36B4* primer sequences reported in [@bib13].c. Do not pre-treat with uracil-N-glycosylase.d. All reactions should be optimized and run in technical triplicate.Using *ACTIN* as an internal standard, calculate the relative *PTEN* and *PTENP1* expression for each sample using the comparative Ct method.a. Additionally perform normalization using *36B4* as an internal standard (additional control).Repeat independently five additional times.

### Deliverables {#s2-1-4}

■ Data to be collected:○ Images of fluorescence and phase/contrast of siGLO transfected cells.○ Purity (A~260/280~ ratio) and concentration of isolated total RNA from cells.○ Raw data for all qPCR reactions.○ Quantification of *PTEN* and *PTENP1* mRNA levels relative to *ACTIN.*○ Quantification of fold change *PTEN* and *PTENP1* mRNA levels relative to siLuc transfected cells. (Compare to Figure 1D).

### Confirmatory analysis plan {#s2-1-5}

This replication attempt will perform the statistical analysis listed below.■ Statistical Analysis:○ Note: at the time of analysis, we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the planned comparisons using the Wilcoxon--Mann Whitney test.○ One-way MANOVA of normalized *PTEN* or *PTENP1* mRNA fold change in siLuc, 19b, or 20a siRNA transfected cells with the following planned comparisons using the Bonferroni correction:*PTEN* mRNA levels of siLuc transfected cells compared to 19b transfected cells.*PTEN* mRNA levels of siLuc transfected cells compared to 20a transfected cells.*PTENP1* mRNA levels of siLuc transfected cells compared to 19b transfected cells.*PTENP1* mRNA levels of siLuc transfected cells compared to 20a transfected cells.■ Meta-analysis of effect sizes:○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.■ Additional exploratory analysis:○ The same analysis described above will be performed with *36B4* normalized values, which serves as an independent normalization control not included in the original analysis.

### Known differences from the original study {#s2-1-6}

The *PTEN* and *PTENP1* mRNA levels will be normalized with an independent control (*36B4*) in addition to *ACTIN*. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-1-7}

The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. Transfection efficiency will be recorded for each replicate and any transfection that does not contain \>90% efficiency will be excluded and not continue through the rest of the procedure. If the efficiency in the first attempt(s) does not obtain \>90%, then any modifications to the transfection protocol will be recorded and the procedure will be maintained for the remaining replicates. The sample purity (A~260/280~ ratio) of the isolated RNA from each sample will be reported. The *PTEN* and *PTENP1* mRNA levels will be normalized with an independent control (*36B4*). All the raw data, including the analysis files, will be uploaded to the project page on the Open Science Framework (OSF) (<https://osf.io/yyqas>) and made publically available.

Protocol 2: Cell growth assay following siRNA transfection {#s2-2}
----------------------------------------------------------

This experiment tests the effect of siRNA mediated depletion of *PTEN*, *PTENP1*, or both on the growth of DU145 cells. It is a replication of Figure 2F.

### Sampling {#s2-2-1}

■ Experiment to be repeated a total of five times for a minimum power of 94%.○ See 'Power calculations' section for details.■ Experiment has 6 conditions:○ Cohort 1: siGENOME non-targeting siRNA \#2 (siLUC) transfected DU145 cells.○ Cohort 2: siPTEN Smartpool (targets *PTEN* and *PTENP1*) transfected DU145 cells.○ Cohort 3: siPTEN transfected DU145 cells.○ Cohort 4: siPTENP1 transfected DU145 cells.○ Cohort 5: Untransfected DU145 cells (additional negative control).○ Transfection control: siGLO RISC-free siRNA transfected DU145 cells.■ Each cohort is harvested on the following days performed in technical triplicate:○ Day 0 (after O/N incubation).○ Day 1.○ Day 2.○ Day 3.○ Day 4.○ Day 5.

### Materials and reagents {#s2-2-2}

ReagentTypeManufacturerCatalog \#CommentsDU145 cellsCell lineATCCHTB-81--RPMI 1640 mediumCell cultureSigma--AldrichR8758Replaces Invitrogen brand used in original studyFetal bovine serum (FBS)Cell cultureSigma--AldrichF2442Replaces Invitrogen brand used in original studyL-glutamineCell cultureSigma--AldrichG7513Original brand not specified100× Penicillin/streptomycinCell cultureSigma--AldrichP4333Original brand not specified0.05% trypsin/0.48 mM EDTACell cultureSigma--AldrichT3924Original brand not specifiedPhosphate buffered saline (PBS), without MgCl~2~ and CaCl~2~Cell cultureSigma--AldrichD8537Original brand not specified12 well tissue culture dishesLabwareCorning3513Original brand not specifiedsiGLO RISC-free siRNANucleic acidDharmaconD-001600-01--siGENOME non-targeting siRNA \#2 (siLUC)Nucleic acidDharmaconD-001210-02--siPTENNucleic acidDharmaconCustomSee Supplemental Figure 6 of original paper for sequenceON-TARGETplus siPTEN SmartpoolNucleic acidDharmaconL-003023-00Composed of: J-003023-09; J-003023-10; J-003023-11; J-003023-12siPTENP1Nucleic acidDharmaconCustomSee Supplemental Figure 6 of original paper for sequenceDharmafect 1Cell cultureDharmaconT-2001-01--MicroscopeInstrumentOlympusLX81Original brand not specifiedCrystal violetDyeSigma--AldrichC0775Original brand not specifiedFormalinChemicalSpecific brand information will be left up to the discretion of the replicating lab and recorded laterAcetic acidChemicalMethanolChemicalSpectrophotometer capable of reading at 590 nm (or 595 nm)InstrumentBioTek InstrumentsSynergy 2 (SLFA configuration)Original brand not specified

### Procedure {#s2-2-3}

#### Note {#s2-2-3-1}

All cells will be sent for mycoplasma testing and STR profiling.DU145 cells grown in complete RPMI 1640: RPMI 1640 supplemented with 2 mM glutamine, 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C and 6% CO~2~.Seed 1.5 × 10^5^ DU145 cells per well in a 12-well dish. Grow overnight.Transfect with 100 nM siRNAs (siPTEN, siPTENP1, siPTEN Smartpool (siPTEN and PTENP1), or siLuc in separate wells) using Dharmafect 1 according to manufacturer\'s instructions or leave untransfected. Transfect control cells with siGLO RISC-free control siRNA according to manufacturer\'s instructions. Grow overnight.Confirm that \>90% of siGLO transfected control cells show fluorescence, indicating they were successfully transfected.a. If transfection is less than 90%, record efficiency for attempt, exclude attempt and do not continue with the rest of the procedure. Repeat procedure until \>90% efficiency is obtained.b. If modification to transfection (step 2) is needed, record and maintain modified steps for remaining replicates.The day after transfection, resuspend 2 × 10^5^ siLuc, siPTEN, siPTENP1, siPTEN/PTENP1, or untransfected cells in 50 ml fresh media. Seed three wells of six sets of 12-well plates with 2 ml of each cell line. Each set of 12 well plates should have three wells of each cell line. Incubate overnight.Fix one plate every 24 hr starting after overnight incubation (the first plate fixed will be called day 0).a. Wash wells once in PBS.b. Fix wells with 10% formalin for 10 min at room temperature.c. Store plates in PBS at 4°C.d. All wells should be fixed by day 6.Stain cells with 0.1% crystal violet, 20% methanol for 15 min. Wash cells.Lyse all wells with 10% acetic acid for 10 min.Read optical density at 590 or 595 nm.a. Reading can be done at 595 nm if 590 is not available.Repeat independently four additional times.

### Deliverables {#s2-2-4}

■ Data to be collected:○ Images of fluorescence and phase/contrast of siGLO transfected cells.○ Raw data of absorbance from plate reader.○ Graph of relative cell number for each cell line over time. (Compare to Figure 2F).

### Confirmatory analysis plan {#s2-2-5}

This replication attempt will perform the following statistical analysis listed below.■ Statistical Analysis:○ Note: at the time of analysis, we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.○ Two-way ANOVA comparing Day 5 absorbance in siLuc, siPTEN, siPTENP1, or siPTEN/PTENP1 transfected cells with the following planned comparisons using the Bonferroni correction:siLuc compared to siPTEN.siLuc compared to siPTENP1.siLuc compared to siPTEN/PTENP1.siPTEN/PTENP1 compared to siPTEN.siPTEN/PTENP1 compared to siPTENP1.○ Two-way ANOVA comparing area under the curve (AUC) measurements (determined from day 0, 1, 2, 3, 4, and 5 for each replicate) from absorbance in siLuc, siPTEN, siPTENP1, or siPTEN/PTENP1 transfected cells with the following planned comparisons using the Bonferroni correction.siLuc compared to siPTEN.siLuc compared to siPTENP1.siLuc compared to siPTEN/PTENP1.siPTEN/PTENP1 compared to siPTEN.siPTEN/PTENP1 compared to siPTENP1.■ Meta-analysis of effect sizes:○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-2-6}

All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-2-7}

The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. Transfection efficiency will be recorded for each replicate and any transfection that does not contain \>90% efficiency will be excluded and not continue through the rest of the procedure. If the efficiency in the first attempt(s) does not obtain \>90%, then any modifications to the transfection protocol will be recorded and the procedure will be maintained for the remaining replicates. All the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/yyqas>) and made publically available.

Protocol 3: Quantitative PCR following transfected with siRNA against PTEN and/or PTENP1 {#s2-3}
----------------------------------------------------------------------------------------

This experiment analyzes the effect of depletion of *PTEN*, *PTENP1*, or both on the mRNA expression of *PTEN* or *PTENP1*. Quantitative real time PCR is utilized to assess the levels of expression following transfection of siRNA. This protocol is a replication of Figure 2G.

### Sampling {#s2-3-1}

■ Experiment to be repeated a total of five times for a minimum power of 89%.○ See 'Power calculations' section for details.■ Experiment has 6 conditons:○ Cohort 1: Uninfected DU145 cells (additional negative control).○ Cohort 1: siGENOME non-targeting siRNA \#2 (siLUC) transfected DU145 cells.○ Cohort 2: siPTEN Smartpool (targets *PTEN* and *PTENP1*) transfected DU145 cells.○ Cohort 3: siPTEN transfected DU145 cells.○ Cohort 4: siPTENP1 transfected DU145 cells.○ Cohort 5: Uninfected DU145 cells (additional negative control).○ Transfection control: siGLO RISC-free siRNA transfected DU145 cells.■ Quantitative RT-PCR performed in technical triplicate for the following genes:○ *PTEN.*○ PTEN1P.○ *ACTIN* (internal control).○ *36B4* (additional internal control).

### Materials and reagents {#s2-3-2}

ReagentTypeManufacturerCatalog \#CommentsDU145 cellsCell lineATCCHTB-81--RPMI 1640 mediumCell cultureSigma--AldrichR8758Replaces Invitrogen brand used in original studyFetal bovine serum (FBS)Cell cultureSigma--AldrichF2442Replaces Invitrogen brand used in original studyL-glutamineCell cultureSigma--AldrichG7513Original brand not specified100× Penicillin/streptomycinCell cultureSigma--AldrichP4333Original brand not specified0.05% trypsin/0.48 mM EDTACell cultureSigma--AldrichT3924Original brand not specifiedPhosphate buffered saline (PBS), without MgCl~2~ and CaCl~2~Cell cultureSigma--AldrichD8537Original brand not specified12 well tissue culture dishesLabwareCorning3513Original brand not specifiedsiGLO RISC-free siRNANucleic acidDharmaconD-001600-01--siGENOME non-targeting siRNA \#2 (siLUC)Nucleic acidDharmaconD-001210-02--ON-TARGETplus siPTEN SmartpoolNucleic acidDharmaconL-003023-00Composed of: J-003023-09; J-003023-10; J-003023-11; J-003023-12siPTENNucleic acidDharmaconCustomSee Supplemental Figure 6 of original paper for sequencesiPTENP1Nucleic acidDharmaconCustomSee Supplemental Figure 6 of original paper for sequenceDharmafect 1Cell cultureDharmaconT-2001-01--MicroscopeInstrumentOlympusLX81Original brand not specified*ACTIN* forward and reverse primersNucleic acidSpecific brand information will be left up to the discretion of the replicating lab and recorded later*PTEN* forward and reverse primersNucleic acid*PTENP1* forward and reverse primersNucleic acid*36B4* forward and reverse primersNucleic acidTRI reagentChemicalSigma--AldrichT9424Replaces Trizol reagent from Invitrogen1-bromo-3-chloropropaseChemicalSigma--AldrichB9673Reagent needed from TRI reagent protocolNuclease free waterChemicalSigma--AldrichW4502Reagent needed from TRI reagent protocolDNase I amplification gradeChemicalSigma--AldrichAMPD1Replaces Invitrogen brand used in original studyFirst-strand cDNA synthesis kit (includes pd(N)6 random hexamers and NotI-(dT)18 primers)KitSigma--AldrichGE27-9261-01Replaces SuperScript II reverse transcriptase from Invitrogen used in original studyQuantiTect Sybr Green PCR kitKitQiagen204141--Real-time PCR machineInstrumentApplied Biosystems7500Replaces Lightcycler 2.0 from Roche used in original study

### Procedure {#s2-3-3}

#### Note {#s2-3-3-1}

All cells will be sent for mycoplasma testing and STR profiling.DU145 cells grown in complete RPMI 1640: RPMI 1640 supplemented with 2 mM glutamine, 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C and 6% CO~2~.Seed 1.5 × 10^5^ DU145 cells per well in a 12-well dish. Grow overnight.Transfect with 100 nM siRNAs (siPTEN, siPTENP1, siPTEN Smartpool (siPTEN/PTENP1), or siLuc in separate wells) using Dharmafect 1 according to manufacturer\'s instructions or leave untransfected. Transfect control cells with siGLO RISC-free control siRNA according to manufacturer\'s instructions. Grow overnight.Confirm that \>90% of siGLO transfected control cells show fluorescence, indicating they were successfully transfected.a. If transfection is less than 90%, record efficiency for attempt, exclude attempt and do not continue with the rest of the procedure. Repeat procedure until \>90% efficiency is obtained.b. If modification to transfection (step 2) is needed, record and maintain modified steps for remaining replicates.24 hr after transfection, extract total RNA directly on the culture dish using TRI reagent and 1-bromo-3-chloropropane according to manufacturer\'s instructions.Treat RNA with DNAse following manufacturer\'s instructions.Reverse transcribe 1 µg RNA/sample into cDNA using first-strand cDNA synthesis kit with primers following manufacturer\'s instructions.a. Record RNA concentration and purity (A~280~/A~260~).Perform quantitative PCR reaction using the QuantiTect Sybr Green PCR kit:a. Use 2 µl of reverse transcription reaction per 20 µl real-time PCR reaction.b. Perform quantitative PCR for *PTEN*, *PTENP1*, *ACTIN*, and *36B4.*i. *PTEN* forward primer: 5′-GTTTACCGGCAGCATCAAAT-3′ii. *PTEN* reverse primer: 5′-CCCCCACTTTAGTGCACAGT-3′iii. *PTENP1* forward primer: 5′-TCAGAACATGGCATACACCAA-3′iv. *PTENP1* reverse primer: 5′-TGATGACGTCCGATTTTTCA-3′v. *ACTIN* forward primer: 5′-CATGTACGTTGCTATCCAGGC-3′vi. *ACTIN* reverse primer: 5′-CTCCTTAATGTCACGCACGAT-3′vii. *36B4* forward primer: 5′-GTGTTCGACAATGGCAGCAT-3′viii. *36B4* reverse primer: 5′-GACACCCTCCAGGAAGCGA-3′i. *36B4* primer sequences reported in [@bib13].c. Do not pre-treat with uracil-N-glycosylase.d. All reactions should be optimized and run in technical triplicate.Using *ACTIN* as an internal standard, calculate the relative *PTEN* and *PTENP1* expression for each sample using the comparative Ct method.a. Additionally perform normalization using *36B4* as an internal standard (additional control).Repeat independently four additional times.

### Deliverables {#s2-3-4}

■ Data to be collected:○ Images of fluorescence and phase/contrast of siGLO transfected cells.○ Purity (A~260/280~ ratio) and concentration of isolated total RNA from cells.○ Raw data for all qPCR reactions.○ Quantification of *PTEN* and *PTENP1* mRNA levels relative to *ACTIN* or *36B4*.○ Quantification of fold change *PTEN* and *PTENP1* mRNA levels relative to siLuc transfected cells.○ Graph of fold change *PTEN* mRNA expression relative to siLuc. (Compare to Figure 2G, left).○ Graph of fold change *PTENP1* mRNA expression relative to siLuc. (Compare to Figure 2G, right).

### Confirmatory analysis plan {#s2-3-5}

This replication attempt will perform the following statistical analysis listed below.■ Statistical Analysis:○ Note: at the time of analysis, we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the planned comparisons using the Wilcoxon--Mann Whitney test.○ One-way MANOVA of *PTEN* and *PTENP1* mRNA levels in siLuc, siPTEN, siPTENP1, or siPTEN/PTENP1 siRNA transfected cells with the following planned comparisons using the Bonferroni correction:*PTEN* mRNA levels of siLuc transfected cells compared to siPTEN transfected cells.*PTEN* mRNA levels of siLuc transfected cells compared to siPTENP1 transfected cells.*PTEN* mRNA levels of siLuc transfected cells compared to siPTEN/PTENP1 transfected cells.*PTENP1* mRNA levels of siLuc transfected cells compared to siPTEN transfected cells.*PTENP1* mRNA levels of siLuc transfected cells compared to siPTENP1 transfected cells.*PTENP1* mRNA levels of siLuc transfected cells compared to siPTEN/PTENP1 transfected cells.■ Meta-analysis of effect sizes:○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.■ Additional exploratory analysis:○ The same analysis described above will be performed with *36B4* normalized values, which serves as an independent normalization control not included in the original analysis.

### Known differences from the original study {#s2-3-6}

The *PTEN* and *PTENP1* mRNA levels will be normalized with an independent control (*36B4*) in addition to *ACTIN*. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-3-7}

The cell line used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. Transfection efficiency will be recorded for each replicate and any transfection that does not contain \>90% efficiency will be excluded and not continue through the rest of the procedure. If the efficiency in the first attempt(s) does not obtain \>90%, then any modifications to the transfection protocol will be recorded and the procedure will be maintained for the remaining replicates. The sample purity (A~260/280~ ratio) of the isolated RNA from each sample will be reported. The *PTEN* and *PTENP1* mRNA levels will be normalized with an independent control (*36B4*). All the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/yyqas>) and made publically available.

Protocol 4: Western blot of cells transfected with siRNA {#s2-4}
--------------------------------------------------------

This experiment utilizes western blot to assess the protein levels of PTEN after depletion of *PTEN*, *PTENP1*, or both. It is a replication of Figure 2H.

### Sampling {#s2-4-1}

■ Experiment to be repeated a total of five times for a minimum power of 80%. The original data are qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.○ See 'Power calculations' section for details.■ Experiment has 6 conditons:○ Cohort 1: siGENOME non-targeting siRNA \#2 (siLUC) transfected DU145 cells.○ Cohort 2: siPTEN Smartpool (targets *PTEN* and *PTENP1*) transfected DU145 cells.○ Cohort 3: siPTEN transfected DU145 cells.○ Cohort 4: siPTENP1 transfected DU145 cells.○ Cohort 5: Uninfected DU145 cells (additional negative control).○ Transfection control: siGLO RISC-free siRNA transfected DU145 cells.■ Western blots performed for:○ PTEN.○ Hsp90 (loading control).

### Materials and reagents {#s2-4-2}

ReagentTypeManufacturerCatalog \#CommentsDU145 cellsCell lineATCCHTB-81--RPMI 1640 mediumCell cultureSigma--AldrichR8758Replaces Invitrogen brand used in original studyFetal bovine serum (FBS)Cell cultureSigma--AldrichF2442Replaces Invitrogen brand used in original studyL-glutamineCell cultureSigma--AldrichG7513Original brand not specified100× Penicillin/streptomycinCell cultureSigma--AldrichP4333Original brand not specified0.05% trypsin/0.48 mM EDTACell cultureSigma--AldrichT3924Original brand not specifiedPhosphate buffered saline (PBS), without MgCl~2~ and CaCl~2~Cell cultureSigma--AldrichD8537Original brand not specified6 well tissue culture dishesLabwareCorning3516Original brand not specifiedsiGLO RISC-free siRNANucleic acidDharmaconD-001600-01--siGENOME non-targeting siRNA \#2 (siLUC)Nucleic acidDharmaconD-001210-02--ON-TARGETplus siPTEN SmartpoolNucleic acidDharmaconL-003023-00Composed of: J-003023-09; J-003023-10; J-003023-11; J-003023-12siPTENNucleic acidDharmaconCustomSee Supplemental Figure 6 of original paper for sequencesiPTENP1Nucleic acidDharmaconCustomSee Supplemental Figure 6 of original paper for sequenceDharmafect 1Cell cultureDharmaconT-2001-01--MicroscopeInstrumentOlympusLX81Original brand not specifiedRabbit anti-PTEN (clone 138G6) monoclonal antibodyAntibodiesCell Signaling9559--Mouse anti-Hsp90 (clone 68) antibodyAntibodiesBecton Dickinson610419Original catalog number not specifiedSecondary antibody (anti-rabbit IgG)AntibodiesCell Signaling7074Original brand not specifiedSecondary antibody (anti-mouse IgG)AntibodiesCell Signaling7076Original brand not specifiedECL DualVue Western Markers (15--150 kDa)Western blot reagentSigma--AldrichGERPN810Original brand not specifiedTrisChemicalSpecific brand information will be left up to the discretion of the replicating lab and recorded laterEDTAChemicalMgCl~2~ChemicalNaClChemicalNP~4~0Chemicalβ-glycerophsphateChemicalNaVO~4~ChemicalNaFChemicalProtease inhibitor cocktail (mammalian)InhibitorSigma--AldrichP8340Original brand not specifiedSonifierInstrumentBranson Digitaln/aOriginal brand not specifiedBradford ReagentReporter assaySigma--AldrichB6916Original brand not specifiedTruPAGE LDS sample buffer (4×)BufferSigma--AldrichPCG3009Original brand not specifiedTruPAGE DTT sample reducer (10×)BufferSigma--AldrichPCG3005--XCell SureLOCK Mini-cell systemInstrumentLife Technologiesn/aOriginal brand not specified4--12% TruPAGE SDS-PAGE gelWestern blot reagentSigma--AldrichPCG2003Replaces NuPage gelsTruPAGE TEA-Tricine SDS running buffer (20×)BufferSigma--AldrichPCG3001Original brand not specifiedXcell II Blot ModuleInstrumentLife Technologiesn/aOriginal brand not specifiedHybond ECL nitrocellulose membraneWestern blot reagentSigma--AldrichGERPN2020DOriginal brand not specifiedTruPAGE transfer buffer (20×)BufferSigma--AldrichPCG3011Original brand not specifiedPonceau S solutionBufferSigma--AldrichP7170--10× Tris buffered saline (TBS)BufferSigma--AldrichT5912Original brand not specifiedECL Prime Western blotting systemDetection assaySigma--AldrichGERPN2232Original brand not specifiedImage JSoftwareNIHVersion 10.2--

### Procedure {#s2-4-3}

#### Note {#s2-4-3-1}

All cells will be sent for mycoplasma testing and STR profiling.DU145 cells grown in complete RPMI 1640: RPMI 1640 supplemented with 2 mM glutamine, 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C and 6% CO~2~.Seed 3.75 × 10^5^ DU145 cells per well in a 6-well dish. Grow overnight.Transfect with 100 nM siRNAs (siPTEN, siPTENP1, siPTEN Smartpool (siPTEN/PTENP1), or siLuc in separate wells) using Dharmafect 1 according to manufacturer\'s instructions or leave untransfected. Transfect control cells with siGLO RISC-free control siRNA according to manufacturer\'s instructions. Grow overnight.Confirm that \>90% of siGLO transfected control cells show fluorescence, indicating they were successfully transfected.a. If transfection is less than 90%, record efficiency for attempt, exclude attempt and do not continue with the rest of the procedure. Repeat procedure until \>90% efficiency is obtained.b. If modification to transfection (step 2) is needed, record and maintain modified steps for remaining replicates.48 hr after transfection lyse cells transfected with siRNAs and uninfected cells in lysis buffer on ice for 30 min.a. Lysis buffer: 50 mM Tris pH8.0, 1 mM EDTA, 1 mM MgCl~2~, 150 mM NaCl, 1% NP-40, 1 mM β-glycerophosphate, 1 mM Na~3~VO~4~, 1 mM NaF, protease inhibitors.Gently sonicate protein lysate for 3 to 4 bursts for 5 to 10 s. Clear lysate by centrifugation at 10,000×*g* for 10 min at 4°C.Perform Bradford protein determination assay following manufacturer\'s instructions.Separate 30 µg of protein (in 1× sample buffer and sample reducer) per lane on a 4--12% Tris Glycine SDS-PAGE gel with protein ladder following manufacturer\'s instructions.a. Sample run per gel:i. Protein molecular weight marker.ii. Untransfected DU145 cells.iii. DU145 cells transfected with siGENOME non-targeting siRNA \#2.iv. DU145 cells transfected with siPTEN.v. DU145 cells transfected with siPTENP1.vi. DU145 cells transfected with siPTEN/PTENP1.Transfer to nitrocellulose membrane (pre-wetted with methanol before use) at 25 V constant for 1--2 hr in 1× transfer buffer with 20% methanol following manufacturer\'s instructions.a. After transfer, stain membrane with Ponceau S solution following manufacturer\'s instructions to visualize transferred protein. Image membrane, then wash out the Ponceau stain (additional quality control step).Perform western blotting with the following antibodies following manufacturer\'s instructions. Use 1× TBS for washes and blocking reagent recommended by manufacturer.a. rabbit anti-PTEN; use at 1:1000 dilution; 54 kDa.b. mouse anti-Hsp90; use at 1:1000 dilution; 90 kDa.Detect signal with appropriate HRP conjugated secondary antibody followed by chemiluminescence following manufacturer\'s instructions.Analyze scanned images using Image J software.a. Equal-sized regions of interest (ROI) will be positioned on specific bands.b. Background will be located within each individual lane but not occupied by any other discrete band.c. Subtract background pixel intensity from ROI pixel intensity.d. Normalize PTEN values by Hsp90 values from the same sample.Repeat independently four additional times.

### Deliverables {#s2-4-4}

■ Data to be collected:○ Images of fluorescence and phase/contrast of siGLO transfected cells.○ Images of Ponceau stained membranes and full films for all western blots with ladder. (Compare to Figure 2H).○ Raw data file of ROI and background pixel intensities.○ Normalize PTEN values for each sample.

### Confirmatory analysis plan {#s2-4-5}

This replication attempt will perform the following statistical analysis listed below.■ Statistical Analysis:○ Note: at the time of analysis, we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.○ Two-way ANOVA of normalized PTEN levels in siLuc, siPTEN, siPTENP1, or siPTEN/PTENP1 siRNA transfected cells with the following planned comparisons using the Bonferroni correction:siLuc compared to siPTEN.siLuc compared to siPTENP1.siLuc compared to siPTEN/PTENP1.siPTEN/PTENP1 compared to siPTEN.siPTEN/PTENP1 compared to siPTENP1.■ Meta-analysis of effect sizes:○ The replication data (mean and 95% confidence interval) will be plotted with the original reported data value plotted as a single point on the same plot for comparison.

### Known differences from the original study {#s2-4-6}

The original study used 12 well plates seeded with 1.5 × 10^5^ DU145 cells per well, which was increased 2.5× to account for the difference in cell surface area. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-4-7}

The cell line used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. Transfection efficiency will be recorded for each replicate and any transfection that does not contain \>90% efficiency will be excluded and not continue through the rest of the procedure. If the efficiency in the first attempt(s) does not obtain \>90%, then any modifications to the transfection protocol will be recorded and the procedure will be maintained for the remaining replicates. Ponceau stained membranes will be used to assess completeness of transfer. All the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/yyqas>) and made publically available.

Protocol 5: Quantitative PCR following PTEN 3′ UTR transfection {#s2-5}
---------------------------------------------------------------

This experiment tests the effect of expressing the 3′ UTR of *PTENP1* on mRNA expression levels of *PTENP1*. It is a replication of the left panel of Figure 4A.

### Sampling {#s2-5-1}

■ Experiment to be repeated a total of three times for a minimum power of 98%.○ See 'Power calculations' section for details.■ Experiment has 3 conditions:○ Cohort 1: pCMV transfected DU145 cells.○ Cohort 2: pCMV/*PTEN* 3′ UTR transfected DU145 cells.○ Cohort 3: Uninfected DU145 cells (additional negative control).■ Quantitative RT-PCR performed in technical triplicate for the following genes:○ *PTENP1*.○ *ACTIN* (internal control).○ *36B4* (additional internal control).

### Materials and reagents {#s2-5-2}

ReagentTypeManufacturerCatalog \#CommentsDU145 cellsCell lineATCCHTB-81--RPMI 1640 mediumCell cultureSigma--AldrichR8758Replaces Invitrogen brand used in original studyFetal bovine serum (FBS)Cell cultureSigma--AldrichF2442Replaces Invitrogen brand used in original studyL-glutamineCell cultureSigma--AldrichG7513Original brand not specified100× Penicillin/streptomycinCell cultureSigma--AldrichP4333Original brand not specified0.05% trypsin/0.48 mM EDTACell cultureSigma--AldrichT3924Original brand not specifiedPhosphate buffered saline (PBS), without MgCl~2~ and CaCl~2~Cell cultureSigma--AldrichD8537Original brand not specified60 mm tissue culture dishesLabwareCorning430166Original brand not specifiedEndo-free maxiprep kitKitSigma--AldrichNA0400--pCMV (empty vector)DNA constructOriginal labn/aFrom original labpCMV/*PTEN* 3′ UTRDNA constructOriginal labn/aFrom original labEffecteneCell cultureQiagen301425Original brand not specified*PTENP1* forward and reverse primersNucleic acidSpecific brand information will be left up to the discretion of the replicating lab and recorded later*ACTIN* forward and reverse primersNucleic acid*36B4* forward and reverse primersNucleic acidTRI reagentChemicalSigma--AldrichT9424Replaces Trizol reagent from Invitrogen1-bromo-3-chloropropaseChemicalSigma--AldrichB9673Reagent needed from TRI reagent protocolNuclease free waterChemicalSigma--AldrichW4502Reagent needed from TRI reagent protocolDNAse I amplification gradeChemicalSigma--AldrichAMPD1Replaces Invitrogen brand used in original studyFirst-strand cDNA synthesis kit (includes pd(N)6 random hexamers and NotI-(dT)18 primers)KitSigma--AldrichGE27-9261-01Replaces SuperScript II reverse transcriptase from Invitrogen used in original studyQuantiTect Sybr Green PCR kitKitQiagen204141--Real-time PCR systemInstrumentApplied Biosystems7500 FastReplaces Roche Lightcycler 2.0 used in original study

### Procedure {#s2-5-3}

#### Note {#s2-5-3-1}

All cells will be sent for mycoplasma testing and STR profiling.DU145 cells grown in complete RPMI 1640: RPMI 1640 supplemented with 2 mM glutamine, 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C and 6% CO~2~.Grow and prepare endotoxin-free plasmid constructs following manufacturer\'s instructions for an endotoxin-free plasmid maxiprep kit.a. pCMV (empty vector).b. pCMV/*PTEN* 3′ UTR.i. Sequence gene of interest in each plasmid and run whole plasmids on agarose gel to confirm vector integrity.Seed 3.5 × 10^5^ DU145 cells per dish in 6 cm dishes. Grow overnight.Transfect with pCMV or pCMV/*PTEN* 3′ UTR plasmids using Effectene according to manufacturer\'s instructions and recommended DNA and reagent amounts.24 hr after transfection, extract total RNA from each cohort directly on the culture dish using TRI reagent and 1-bromo-3-chloropropane according to manufacturer\'s instructions.Treat RNA with DNase I following manufacturer\'s instructions.Reverse transcribe 1 µg RNA/sample into cDNA using first-strand cDNA synthesis kit with primers following manufacturer\'s instructions.a. Record RNA concentration and purity (A~280~/A~260~).Perform quantitative PCR reaction using the QuantiTect SYBR Green PCR kit:a. Use 2 µl of reverse transcription reaction per 20 µl real-time PCR reaction.b. Perform quantitative PCR for *PTENP1*, *ACTIN*, and *36B4.*i. *PTENP1* forward primer: 5′-TCAGAACATGGCATACACCAA-3′ii. *PTENP1* reverse primer: 5′-TGATGACGTCCGATTTTTCA-3′iii. *ACTIN* forward primer: 5′-CATGTACGTTGCTATCCAGGC-3′iv. *ACTIN* reverse primer: 5′-CTCCTTAATGTCACGCACGAT-3′v. *36B4* forward primer: 5′-GTGTTCGACAATGGCAGCAT-3′vi. *36B4* reverse primer: 5′-GACACCCTCCAGGAAGCGA-3′c. *36B4* primer sequences reported in [@bib13].d. Do not pre-treat with uracil-N-glycosylase.e. All reactions should be optimized and run in technical triplicate.Using *ACTIN* as an internal standard, calculate the fold change in *PTEN1P* expression relative to pCMV expressing cells using the comparative Ct method.a. Additionally perform normalization using *36B4* as an internal standard (additional control).Repeat independently two additional times.

### Deliverables {#s2-5-4}

■ Data to be collected:○ Purity (A~260/280~ ratio) and concentration of isolated total RNA from cells.○ Raw data for all qPCR reactions.○ Quantification of *PTENP1* mRNA levels relative to *ACTIN* or *36B4.*○ Quantification of fold change *PTENP1* mRNA levels relative to pCMV transfected cells. (Compare to Figure 4A, left panel).

### Confirmatory analysis plan {#s2-5-5}

This replication attempt will perform the following statistical analysis listed below.■ Statistical Analysis:○ Note: at the time of analysis, we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.○ Unpaired two-tailed *t*-test of *PTENP1* mRNA levels of pCMV transfected cells compared to pCMV/*PTEN* 3′ UTR transfected cells.■ Meta-analysis of effect sizes:○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.■ Additional exploratory analysis:○ The same analysis described above will be performed with *36B4* normalized values, which serves as an independent normalization control not included in the original analysis.

### Known differences from the original study {#s2-5-6}

The *PTENP1* mRNA levels will be normalized with an independent control (*36B4*) in addition to *ACTIN*. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-5-7}

The cell line used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. The sample purity (A~260/280~ ratio) of the isolated RNA from each sample will be reported. The *PTENP1* mRNA levels will be normalized with an independent control (*36B4*). All the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/yyqas>) and made publically available.

Protocol 6: Cell growth assay following PTEN 3′ UTR transfection {#s2-6}
----------------------------------------------------------------

This experiment tests the effect of expressing the 3′ UTR of PTENP1 on cell growth. It is a replication of the right panel of Figure 4A.

### Sampling {#s2-6-1}

■ Experiment to be repeated a total of three times for a minimum power of 98%.○ See 'Power calculations' section for details.■ Experiment has 3 conditions:○ Cohort 1: pCMV transfected DU145 cells.○ Cohort 2: pCMV/*PTEN* 3′ UTR transfected DU145 cells.○ Cohort 3: Uninfected DU145 cells (additional negative control).■ Each cohort is harvested on the following days performed in technical triplicate:○ Day 0 (after O/N incubation).○ Day 1.○ Day 2.○ Day 3.○ Day 4.○ Day 5.

### Materials and reagents {#s2-6-2}

ReagentTypeManufacturerCatalog \#CommentsDU145 cellsCell lineATCCHTB-81--RPMI 1640 mediumCell cultureSigma--AldrichR8758Replaces Invitrogen brand used in original studyFetal bovine serum (FBS)Cell cultureSigma--AldrichF2442Replaces Invitrogen brand used in original studyL-glutamineCell cultureSigma--AldrichG7513Original brand not specified100× Penicillin/streptomycinCell cultureSigma--AldrichP4333Original brand not specified0.05% trypsin/0.48 mM EDTACell cultureSigma--AldrichT3924Original brand not specifiedPhosphate buffered saline (PBS), without MgCl~2~ and CaCl~2~Cell cultureSigma--AldrichD8537Original brand not specified60 mm tissue culture dishesLabwareCorning430166Original brand not specifiedpCMV (empty vector)DNA constructOriginal labn/aFrom original labpCMV/*PTEN* 3′ UTRDNA constructOriginal labn/aFrom original labEffecteneCell cultureQiagen301425Original brand not specified12 well tissue culture dishesLabwareCorning3513Original brand not specifiedCrystal violetDyeSigma--AldrichC0775Original brand not specifiedFormalinChemicalSpecific brand information will be left up to the discretion of the replicating lab and recorded laterAcetic acidChemicalMethanolChemicalSpectrophotometer capable of reading at 590 nm (or 595 nm)InstrumentAlamolabsOriginal brand not specified

### Procedure {#s2-6-3}

#### Note {#s2-6-3-1}

All cells will be sent for mycoplasma testing and STR profiling.DU145 cells grown in complete RPMI 1640: RPMI 1640 supplemented with 2 mM glutamine, 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C and 6% CO~2~.Seed 3.5 × 10^5^ DU145 cells per dish in 6 cm dishes. Grow overnight.Transfect with pCMV or pCMV/*PTEN* 3′ UTR plasmids using Effectene according to manufacturer\'s instructions and recommended DNA and reagent amounts.a. Plasmids prepped in Protocol 7.6 hr after transfection, resuspend 2 × 10^5^ pCMV, pCMV/*PTEN* 3′ UTR, and untransfected cells in 50 ml fresh media. Seed three wells of six sets of 12-well plates with 2 ml of each cell line. Each set of 12 well plates should have three wells containing untransfected cells, three wells containing pCMV-transfected cells, and three wells containing pCMV/PTEN 3′ UTR-transfected cells. Incubate overnight.Fix one plate every 24 hr starting after overnight incubation (the first plate fixed will be called day 0).a. Wash wells once in PBS.b. Fix wells with 10% formalin for 10 min at room temperature.c. Store plates in PBS at 4°C.d. All wells should be fixed by day 6.Stain cells with 0.1% crystal violet, 20% methanol for 15 min. Wash cells.Lyse all wells with 10% acetic acid for 10 min.Read optical density at 590 nm.a. Reading can be done at 595 nm if 590 nm is not available.Repeat independently two additional times.

### Deliverables {#s2-6-4}

■ Data to be collected:○ Raw data of absorbance from plate reader.○ Relative absorbance for each cohort over time. (Compare to Figure 4A, right panel).

### Confirmatory analysis plan {#s2-6-5}

This replication attempt will perform the following statistical analysis listed below.■ Statistical Analysis:○ Note: at the time of analysis, we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.○ Unpaired two-tailed *t*-test of Day 5 absorbance of pCMV transfected cells compared to pCMV/*PTEN* 3′ UTR transfected cells.○ Unpaired two-tailed *t*-test of AUC measurements (determined from day 0, 1, 2, 3, 4, and 5 for each replicate) of pCMV transfected cells compared to pCMV/*PTEN* 3′ UTR transfected cells.■ Meta-analysis of effect sizes:○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-6-6}

All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-6-7}

The cell line used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. All the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/yyqas>) and made publically available.

Power calculations {#s3}
==================

For additional details on power calculations, please see analysis scripts and associated files on the OSF:

<https://osf.io/cd2yq/>

Protocol 1 {#s3-1}
----------

Summary of original data estimated from graph reported in Figure 1D:siRNAmRNAMeanStdevNsiLUC*PTEN*1.000.2393*PTENP1*1.000.386319b*PTEN*0.2860.0853*PTENP1*0.2340.065320a*PTEN*0.4580.1673*PTENP1*0.2500.0803

### Test family {#s3-1-1}

■ 2 tailed *t* test, Wilcoxon--Mann-Whitney test, Bonferroni\'s correction: alpha error = 0.0125.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizesiLuc *PTEN* mRNA19b *PTEN* mRNA3.9855591.9%[\*](#tblfn1){ref-type="table-fn"}4[\*](#tblfn1){ref-type="table-fn"}4[\*](#tblfn1){ref-type="table-fn"}siLuc *PTEN* mRNA20a *PTEN* mRNA2.6299988.3%66siLuc *PTENP1* mRNA19b *PTENP1* mRNA2.7653280.7%[†](#tblfn2){ref-type="table-fn"}5[†](#tblfn2){ref-type="table-fn"}5[†](#tblfn2){ref-type="table-fn"}siLuc *PTENP1* mRNA20a *PTENP1* mRNA2.6890889.8%66[^1][^2]

### Test family {#s3-1-2}

■ Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.■ Two-way ANOVA: Fixed effects, special, main effects and interactions: alpha error = 0.05.○ Due to a lack of raw original data, we are unable to perform power calculations using a MANOVA. We are using a two-way ANOVA to estimate sample size.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).

ANOVA F test statistic and partial η^2^ performed with R software, version 3.1.2 ([@bib34]).GroupsF test statisticPartial η^2^Effect size *f*A priori powerTotal sample sizesiLUC, 19b, 20a (*PTEN* and *PTENP1* mRNA for all)F(2,12) = 23.1978 (main effect: siRNA)0.794511.9662996.3%[\*](#tblfn3){ref-type="table-fn"}9[\*](#tblfn3){ref-type="table-fn"} (6 groups)[^3]

### Test family {#s3-1-3}

■ Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.■ 2 tailed *t* test, difference between two independent means, Bonferroni\'s correction: alpha error = 0.0125.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizesiLuc *PTEN* mRNA19b *PTEN* mRNA3.9855594.2%[\*](#tblfn4){ref-type="table-fn"}4[\*](#tblfn4){ref-type="table-fn"}4[\*](#tblfn4){ref-type="table-fn"}siLuc *PTEN* mRNA20a *PTEN* mRNA2.6299990.6%66siLuc *PTENP1* mRNA19b *PTENP1* mRNA2.7653284.0%[†](#tblfn5){ref-type="table-fn"}5[†](#tblfn5){ref-type="table-fn"}5[†](#tblfn5){ref-type="table-fn"}siLuc *PTENP1* mRNA20a *PTENP1* mRNA2.6890881.6%[‡](#tblfn6){ref-type="table-fn"}5[‡](#tblfn6){ref-type="table-fn"}5[‡](#tblfn6){ref-type="table-fn"}[^4][^5][^6]

Protocol 2 {#s3-2}
----------

Summary of original data estimated from graph reported in Figure 2F:siRNADayMeanStdevNsiLuc01.0000310.9550.108320.9280.108331.2520.108341.3150.108351.6040.1083siPTEN01.0000311.1980.108321.3060.108332.0450.108342.4140.108354.1530.2343siPTENP101.0000311.1620.108321.0990.108331.6130.108341.7750.108352.6130.1083siPTEN/PTENP101.0000311.1980.108321.3870.108332.3960.108343.0990.108355.4140.1713

AUC calculations from estimated values.

Calculations performed with R software 3.1.2 ([@bib34]).siRNADaysMeanStdevNsiLuc0, 1, 2, 3, 4, 55.7520.4863siPTEN0, 1, 2, 3, 4, 59.5410.5503siPTENP10, 1, 2, 3, 4, 57.4550.4863siPTEN/PTENP10, 1, 2, 3, 4, 511.2880.5183

### Test family {#s3-2-1}

■ Two-way ANOVA: Fixed effects, special, main effects and interactions: alpha error = 0.05.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).

ANOVA F test statistic and partial η^2^ performed with R software, version 3.1.2 ([@bib34]).

### Day 5 values {#s3-2-2}

GroupsF test statisticPartial η^2^Effect size *f*A priori powerTotal sample sizesiLUC, siPTEN, siPTENP1, siPTEN/PTENP1F(1,8) = 798.9603 (main effect: siPTEN)0.990099.9933792.0%[\*](#tblfn7){ref-type="table-fn"}5[\*](#tblfn7){ref-type="table-fn"} (4 groups)F(1,8) = 143.7867 (main effect: siPTENP1)0.947294.2394899.5%[\*](#tblfn7){ref-type="table-fn"}6[\*](#tblfn7){ref-type="table-fn"} (4 groups)[^7]

### AUC values {#s3-2-3}

GroupsF test statisticPartial η2Effect size fA priori powerTotal sample sizesiLUC, siPTEN, siPTENP1, siPTEN/PTENP1F(1,8) = 166.9731 (main effect: siPTEN)0.954284.5685799.8%[\*](#tblfn8){ref-type="table-fn"}6[\*](#tblfn8){ref-type="table-fn"} (4 groups)F(1,8) = 34.2219 (main effect: siPTENP1)0.810532.0682793.9%[\*](#tblfn8){ref-type="table-fn"}7[\*](#tblfn8){ref-type="table-fn"} (4 groups)[^8]

### Test family {#s3-2-4}

■ 2 tailed *t* test, difference between two independent means, Bonferroni\'s correction: alpha error = 0.01.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).

### Day 5 values {#s3-2-5}

Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizesiLucsiPTEN15.5499491.1%[\*](#tblfn9){ref-type="table-fn"}2[\*](#tblfn9){ref-type="table-fn"}2[\*](#tblfn9){ref-type="table-fn"}siLucsiPTENP16.1540491.1%[\*](#tblfn9){ref-type="table-fn"}3[\*](#tblfn9){ref-type="table-fn"}3[\*](#tblfn9){ref-type="table-fn"}siLucsiPTEN/PTENP123.2424999.9%[\*](#tblfn9){ref-type="table-fn"}2[\*](#tblfn9){ref-type="table-fn"}2[\*](#tblfn9){ref-type="table-fn"}siPTEN/PTENP1siPTEN7.6925599.4%[\*](#tblfn9){ref-type="table-fn"}3[\*](#tblfn9){ref-type="table-fn"}3[\*](#tblfn9){ref-type="table-fn"}siPTEN/PTENP1siPTENP117.0884594.6%[\*](#tblfn9){ref-type="table-fn"}2[\*](#tblfn9){ref-type="table-fn"}2[\*](#tblfn9){ref-type="table-fn"}[^9]

### AUC values {#s3-2-6}

Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizesiLucsiPTEN7.4163699.1%[\*](#tblfn10){ref-type="table-fn"}3[\*](#tblfn10){ref-type="table-fn"}3[\*](#tblfn10){ref-type="table-fn"}siLucsiPTENP13.3333993.8%55[\*](#tblfn10){ref-type="table-fn"}siLucsiPTEN/PTENP110.8379499.9%[\*](#tblfn10){ref-type="table-fn"}3[\*](#tblfn10){ref-type="table-fn"}3[\*](#tblfn10){ref-type="table-fn"}siPTEN/PTENP1siPTEN3.4215881.3%[†](#tblfn20){ref-type="table-fn"}4[†](#tblfn20){ref-type="table-fn"}4[†](#tblfn20){ref-type="table-fn"}siPTEN/PTENP1siPTENP17.5045499.3%[\*](#tblfn10){ref-type="table-fn"}3[\*](#tblfn10){ref-type="table-fn"}3[\*](#tblfn10){ref-type="table-fn"}[^10][^11]

Protocol 3 {#s3-3}
----------

Summary of original data estimated from graph reported in Figure 2G:siRNAmRNAMeanStdevNsiLUC*PTEN*1.0000.2493*PTENP1*1.0000.1553siPTEN*PTEN*0.1160.0653*PTENP1*0.5430.0993siPTENP1*PTEN*0.3810.0863*PTENP1*0.2690.0943siPTEN/PTENP1*PTEN*0.1930.0673*PTENP1*0.4820.1613

### Test family {#s3-3-1}

■ 2 tailed *t* test, Wilcoxon--Mann-Whitney test, Bonferroni\'s correction: alpha error = 0.008333.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizesiLuc *PTEN* mRNAsiPTEN *PTEN* mRNA4.8588496.8%[\*](#tblfn11){ref-type="table-fn"}4[\*](#tblfn11){ref-type="table-fn"}4[\*](#tblfn11){ref-type="table-fn"}siLuc *PTENP1* mRNAsiPTEN *PTENP1* mRNA3.5253793.1%55siLuc *PTEN* mRNAsiPTENP1 *PTEN* mRNA3.3226789.7%55siLuc *PTENP1* mRNAsiPTENP1 *PTENP1* mRNA5.7074583.9%[†](#tblfn12){ref-type="table-fn"}3[†](#tblfn12){ref-type="table-fn"}3[†](#tblfn12){ref-type="table-fn"}siLuc *PTEN* mRNAsiPTEN/PTENP1 *PTEN* mRNA4.4265893.2%[‡](#tblfn13){ref-type="table-fn"}4[‡](#tblfn13){ref-type="table-fn"}4[‡](#tblfn13){ref-type="table-fn"}siLuc *PTENP1* mRNAsiPTEN/PTENP1 *PTENP1* mRNA3.2758588.7%55[^12][^13][^14]

### Test family {#s3-3-2}

■ Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.■ Two-way ANOVA: Fixed effects, special, main effects and interactions: alpha error = 0.05.○ Due to a lack of raw original data, we are unable to perform power calculations using a MANOVA. We are using a two-way ANOVA to estimate sample size.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).

ANOVA F test statistic and partial η^2^ performed with R software, version 3.1.2 ([@bib34]).GroupsF test statisticPartial η^2^Effect size *f*A priori powerTotal sample sizesiLUC, siPTEN, siPTENP1, siPTEN/PTENP1 (*PTEN* and *PTENP1* mRNA for all)F(3,16) = 36.6570 (main effect: siRNA)0.872992.6216894.9%[\*](#tblfn14){ref-type="table-fn"}11[\*](#tblfn14){ref-type="table-fn"} (8 groups)[^15]

### Test family {#s3-3-3}

■ Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.■ 2 tailed *t* test, difference between two independent means, Bonferroni\'s correction: alpha error = 0.008333.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizesiLuc *PTEN* mRNAsiPTEN *PTEN* mRNA4.8588498.1%[\*](#tblfn15){ref-type="table-fn"}4[\*](#tblfn15){ref-type="table-fn"}4[\*](#tblfn15){ref-type="table-fn"}siLuc *PTENP1* mRNAsiPTEN *PTENP1* mRNA3.5253780.8%[†](#tblfn16){ref-type="table-fn"}4[†](#tblfn16){ref-type="table-fn"}4[†](#tblfn16){ref-type="table-fn"}siLuc *PTEN* mRNAsiPTENP1 *PTEN* mRNA3.3226792.2%55siLuc *PTENP1* mRNAsiPTENP1 *PTENP1* mRNA5.7074589.1%[‡](#tblfn17){ref-type="table-fn"}3[‡](#tblfn17){ref-type="table-fn"}3[‡](#tblfn17){ref-type="table-fn"}siLuc *PTEN* mRNAsiPTEN/PTENP1 *PTEN* mRNA4.4265895.4%[§](#tblfn18){ref-type="table-fn"}4[§](#tblfn18){ref-type="table-fn"}4[§](#tblfn18){ref-type="table-fn"}siLuc *PTENP1* mRNAsiPTEN/PTENP1 *PTENP1* mRNA3.2758591.4%55[^16][^17][^18][^19]

Protocol 4 {#s3-4}
----------

Summary of original data reported in Figure 2H:siRNARelative PTEN signalsiLuc1.00siPTEN0.50siPTENP10.60siPTEN/PTENP10.10

The original data do not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.

### Test family {#s3-4-1}

■ Two-way ANOVA: Fixed effects, special, main effects and interactions: alpha error = 0.05.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).

ANOVA F test statistic and partial η^2^ performed with R software, version 3.1.2 ([@bib34]).

2% variance:GroupsF test statisticPartial η^2^Effect size *f*A priori powerTotal sample sizesiLUC, siPTEN, siPTENP1, siPTEN/PTENP1F(1,8) = 4629.6 (main effect: siPTEN)0.9982824.056499.9%8 (4 groups)F(1,8) = 2963.0 (main effect: siPTENP1)0.9973119.2440499.9%8 (4 groups)

15% variance:GroupsF test statisticPartial η^2^Effect size *f*A priori powerTotal sample sizesiLUC, siPTEN, siPTENP1, siPTEN/PTENP1F(1,8) = 82.3050 (main effect: siPTEN)0.911413.2075099.9%8 (4 groups)F(1,8) = 52.6750 (main effect: siPTENP1)0.868152.5660099.9%8 (4 groups)

28% variance:GroupsF test statisticPartial η^2^Effect size *f*A priori powerTotal sample sizesiLUC, siPTEN, siPTENP1, siPTEN/PTENP1F(1,8) = 23.6210 (main effect: siPTEN)0.747001.7183094.5%8 (4 groups)F(1,8) = 15.1170 (main effect: siPTENP1)0.653941.3746482.4%8 (4 groups)

40% variance:GroupsF test statisticPartial η^2^Effect size *f*A priori powerTotal sample sizesiLUC, siPTEN, siPTENP1, siPTEN/PTENP1F(1,8) = 11.5741 (main effect: siPTEN)0.591301.2028195.3%12 (4 groups)F(1,8) = 7.4074 (main effect: siPTENP1)0.480770.9622583.0%12 (4 groups)

### Test family {#s3-4-2}

■ 2 tailed *t* test, difference between two independent means, Bonferroni\'s correction: alpha error = 0.01.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).

2% variance:Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizesiLucsiPTEN39.2839999.9%22siLucsiPTENP131.4271999.9%22siLucsiPTEN/PTENP170.7111899.9%22siPTEN/PTENP1siPTEN31.4271999.9%22siPTEN/PTENP1siPTENP139.2839999.9%22

15% variance:Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizesiLucsiPTEN5.2378286.6%33siLucsiPTENP14.1902686.6%44siLucsiPTEN/PTENP19.4280899.9%33siPTEN/PTENP1siPTEN4.1902694.6%44siPTEN/PTENP1siPTENP15.2378286.6%33

28% variance:Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizesiLucsiPTEN2.8060382.0%55siLucsiPTENP12.2448284.8%77siLucsiPTEN/PTENP15.0508584.0%33siPTEN/PTENP1siPTEN2.2448284.8%77siPTEN/PTENP1siPTENP12.8060382.0%55

40% variance:Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizesiLucsiPTEN1.9641986.9%88siLucsiPTENP11.5713584.7%1212siLucsiPTEN/PTENP13.5355491.0%44siPTEN/PTENP1siPTEN1.5713583.6%1212siPTEN/PTENP1siPTENP11.9641981.0%88

In order to produce quantitative replication data, we will run the experiment five times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.

Protocol 5 {#s3-5}
----------

Summary of original data estimated from graph reported in Figure 4A, left panel:PlasmidMeanStdevNpCMV1.0000.5413pCMV/*PTEN* 3′ UTR3.8800.7073

### Test family {#s3-5-1}

■ 2 tailed *t* test, difference between two independent means, alpha error = 0.05.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizepCMVpCMV/*PTEN* 3′ UTR4.5744698.2%33

Protocol 6 {#s3-6}
----------

Summary of original data estimated from graph reported in Figure 4A, right panel:PlasmidDayMeanStdevNpCMV01.0000311.0000.119321.2380.119331.9170.119345.7260.119357.1670.1193pCMV/*PTEN* 3′ UTR01.0000311.0000.119321.1430.119331.9170.119344.1550.214355.2380.1193

AUC calculations from estimated values.

Calculations performed with R software 3.1.2 ([@bib34]).PlasmidDaysMeanStdevNpCMV0, 1, 2, 3, 4, 513.9640.5363pCMV/*PTEN* 3′ UTR0, 1, 2, 3, 4, 511.3330.6313

### Test family {#s3-6-1}

■ 2 tailed *t* test, difference between two independent means, alpha error = 0.05.

'Power calculations' performed with G\*Power software, version 3.1.7 ([@bib10]).

### Day 5 values {#s3-6-2}

Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizepCMVpCMV/*PTEN* 3′ UTR16.2000099.9%2[\*](#tblfn19){ref-type="table-fn"}2[\*](#tblfn19){ref-type="table-fn"}[^20]

### AUC values {#s3-6-3}

Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizepCMVpCMV/*PTEN* 3′ UTR4.4952697.9%33

Funding Information
===================

This paper was supported by the following grant:

-   Laura and John Arnold foundation to .

The Reproducibility Project: Cancer Biology core team would like to thank the original authors, in particular Laura Poliseno, Leonardo Salmena, and Pier Paolo Pandolfi, for generously sharing critical information as well as reagents to ensure the fidelity and quality of this replication attempt. We thank Courtney Soderberg at the Center for Open Science for assistance with statistical analyses. We would also like to thank the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology; American Type Culture Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma--Aldrich, and System Biosciences (SBI). We thank Dale Cowley and Kumar Pandya, TransViragen, Inc., for technical suggestions related to experiments to be performed.

Additional information {#s4}
======================

IK: Alamo Laboratories Inc. is a Science Exchange associated laboratory.

JK: Biotechnology Research and Education Program, University of Maryland is a Science Exchange associated laboratory.

RP:CB: EI, FT, JL, and NP are employed and holds shares in Science Exchange Inc.

The other authors declare that no competing interests exist.

IK, Drafting or revising the article.

JK, Drafting or revising the article.

KO, Drafting or revising the article.

EG, Drafting or revising the article.

RP:CB, Conception and design, Drafting or revising the article.

10.7554/eLife.08245.002

Decision letter

Davis

Roger

Reviewing editor

Howard Hughes Medical Institute & University of Massachusetts Medical School

,

United States

eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled "Registered report: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology" for peer review at *eLife*. Your submission has been favorably evaluated by Charles Sawyers (Senior Editor), and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed their comments with one another, and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This Registered Report describes a proposed replication study that is focused on Poliseno et al. (2010, Nature 465, 1033-1038). The central conclusion of [@bib26] is that expression of an endogenous miRNA competitor (e.g. a pseudogene) can de-repress miRNA function.

There are four important points that the authors should address:

1\) The Introduction lays out the background, the results of [@bib26], and consistent data reported in other studies. However, the Introduction should include other studies that lead to questions concerning the ceRNA hypothesis (e.g. PMID: 24793693 & PMID: 24905003 and references therein). The ceRNA hypothesis remains an active area for inquiry. The impression given by the Introduction is that the overwhelming balance of evidence favors the ceRNA hypothesis -- this is not correct.

2\) It is well established that over-expression of miRNA can repress target mRNA (Figure 1D) and that over-expression of a miRNA sponge can de-repress a miRNA target (Figure 2A-D and Figure 4A). While repetition of these figures panels is useful, none of these experiments tackle the central conclusions of [@bib26] -- that expression of an endogenous miRNA competitor (e.g. a pseudogene) can de-repress miRNA function. This is because of the reliance on over-expression strategies in Figure 1D, Figure 2A-D, and Figure 4A. Studies of the endogenous genes are required to test reproducibility of the central conclusion of the original study.

The major conclusion of [@bib26] is that decreased expression of *PTEN* or *PTENP1* mRNA should cause mutual changes in miRNA-mediated repression. The only experimental test on endogenous *PTEN* and *PTENP1* mRNA (rather than over-expression of cDNA or miRNA) is represented by Figure 2F-H. It is therefore essential that Figure 2F-H are the focus of the replication study because these are the only experiments that address the central conclusion of [@bib26].

3\) The normalization used for the mRNA measurements by [@bib26] and this Registered Report is *ACTIN*. This is a problem because Actin mRNA is dynamically regulated in cells and is a target of cell signaling pathway. Perhaps the *ACTIN* measurements can be retained in the replication study, but we would strongly recommend that an independent normalization control is also employed -- for example *36B4* or another control gene.

4\) The authors adopt two statistical procedures, ANOVA and 2 tailed *t*-test, in the analysis. However, neither of them is used correctly. Take Protocol 1 as an example.

A\) In ANOVA, for testing the main effect of siRNA, there are only 3 different levels: siLUC, *19b* and *20a*, but the numerator degree of freedom of the F-test is stated to be 4 by the authors. I also couldn\'t follow how the authors got the denominator d.f. to be 20 given there are only 18 observations in total.

B\) In 2 tailed *t*-test, the effective size calculated by the authors assumed that the two populations have the same variance, which is apparently not true for many pairs, according to the data. For example, in the comparison of siLuc *PTENP1* and *19b PTENP1*, the two sample standard deviations are 0.386 and 0.065, respectively. The former is almost 6-fold of the later. Moreover, given this small sample size, *t*-test is not recommended unless one is very confident that the two population distributions are normal.

5\) Besides the paper that the authors intend to replicate, the oncosuppressive properties of *PTEN* 3\'UTR have been shown also in Tay et al. ([Cell, 2015]{.ul}), a paper which should be quoted. Analogously, the oncosuppressive properties of *PTENP1* have been shown in other papers besides [@bib41], namely [@bib6] and [@bib15].

6\) In more general terms, we suggest that the Introduction should include a comprehensive review of all the papers in which the ceRNA-based relationship between *PTEN* and *PTENP1* has been confirmed:

Poliseno, L., et al., Deletion of *PTENP1* pseudogene in human melanoma. J Invest [Dermatol, 2011]{.ul}. 131(12): p. 2497-500.

Ioffe, Y.J., et al., Phosphatase and tensin homolog (*PTEN*) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis? Gynecol [Oncol, 2012]{.ul}. 124(2): p. 340-6.

Johnsson, P., et al., A pseudogene long-noncoding-RNA network regulates *PTEN* transcription and translation in human cells. Nat Struct Mol [Biol, 2013]{.ul}. 20(4): p. 440-6.

Yu, G., et al., Pseudogene *PTENP1* functions as a competing endogenous RNA to suppress clear cell renal cell carcinoma progression. Mol Cancer [Ther, 2014]{.ul}.

Chen, C.L., et al., Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA *PTENP1* and MicroRNA regulation. [Biomaterials, 2015]{.ul}. 44: p. 71-81.

Guo, X., et al., Pseudogene *PTENP1* Suppresses Gastric Cancer Progression by Modulating *PTEN*. Anticancer Agents Med [Chem, 2015]{.ul}.

10.7554/eLife.08245.003

Author response

*1) The Introduction lays out the background, the results of* [@bib26]*, and consistent data reported in other studies. However, the Introduction should include other studies that lead to questions concerning the ceRNA hypothesis (e.g. PMID: 24793693 & PMID: 24905003 and references therein). The ceRNA hypothesis remains an active area for inquiry. The impression given by the Introduction is that the overwhelming balance of evidence favors the ceRNA hypothesis -- this is not correct*.

We have updated the Introduction to include these references and reflect a more balanced view of the ceRNA hypothesis.

*2) It is well established that over-expression of miRNA can repress target mRNA (Figure 1D) and that over-expression of a miRNA sponge can de-repress an miRNA target (Figure 2A-D and Figure 4A). While repetition of these figures panels is useful, none of these experiments tackle the central conclusions of* [@bib26] *-- that expression of an endogenous miRNA competitor (e.g. a pseudogene) can de-repress miRNA function. This is because of the reliance on over-expression strategies in Figure 1D, Figure 2A-D, and Figure 4A. Studies of the endogenous genes are required to test reproducibility of the central conclusion of the original study*.

*The major conclusion of* [@bib26] *is that decreased expression of* PTEN *or* PTENP1 *mRNA should cause mutual changes in miRNA-mediated repression. The only experimental test on endogenous* PTEN *and* PTENP1 *mRNA (rather than over-expression of cDNA or miRNA) is represented by Figure 2F-H. It is therefore essential that Figure 2F-H are the focus of the replication study because these are the only experiments that address the central conclusion of* [@bib26].

Thank you for the suggestion. We have included Figures 2F-H in the revised manuscript. We are also removing Figures 2A, 2C, and 2D from the replication attempt.

*3) The normalization used for the mRNA measurements by* [@bib26] *and the Registered Report is* ACTIN*. This is a problem because Actin mRNA is dynamically regulated in cells and is a target of cell signaling pathway. Perhaps the* ACTIN *measurements can be retained in the replication study, but I would strongly recommend that an independent normalization control is also employed -- for example* 36B4 *or another control gene*.

Thank you for the suggestion. We have included *36B4* as an additional control gene. We will maintain the original analysis (using *ACTIN* measurements for normalization) and include an additional exploratory analysis from the original, using *36B4* to normalize the gene expression.

*4) The authors adopt two statistical procedures, ANOVA and 2 tailed* t*-test, in the analysis. However, neither of them is used correctly. Take Protocol 1 as an example*.

*A) In ANOVA, for testing the main effect of siRNA, there are only 3 different levels: siLUC,* 19b *and* 20a*, but the numerator degree of freedom of the F-test is stated to be 4 by the authors. I also couldn\'t follow how the authors got the denominator d.f. to be 20 given there are only 18 observations in total*.

Thank you for catching this error. We have gone through and checked all calculations. Regarding Protocol 1 in particular, the error with d.f. was an error upon transferring the information to the manuscript. The d.f. of the F-test is indeed (2,12) (3 levels with 18 total measurements). We have corrected any other location where this might have occurred in error.

*B) In 2 tailed* t*-test, the effective size calculated by the authors assumed that the two populations have the same variance, which is apparently not true for many pairs according to the data. For example, in the comparison of siLuc* PTENP1 *and* 19b PTENP1*, the two sample standard deviations are 0.386 and 0.065, respectively. The former is almost 6-fold of the later. Moreover, given this small sample size,* t*-test is not recommended unless one is very confident that the two population distributions are normal*.

Thank you for the comment. We have gone through and included non-parametric comparisons (Wilcoxon-Mann-Whitney) along with the student's *t*-tests whenever the standard deviations are large. We have also included a statement in the confirmatory analysis plan where the normality and homoscedasticity of the data will be assessed prior to performing the proposed statistical analysis.

We have also included a link to the scripts, other files, and summary of calculations (<https://osf.io/cd2yq/?view_only=c9c2497ac93c46b6a8ab786769fcff74>).

*5) Besides the paper that the authors intend to replicate, the oncosuppressive properties of* PTEN *3\'UTR have been shown also in Tay et al. ([Cell, 2015]{.ul}), a paper which should be quoted. Analogously, the oncosuppressive properties of* PTENP1 *have been shown in other papers besides* [@bib41]*, namely* [@bib6] *and* [@bib15].

We have updated the Introduction to reflect a more balanced view of the ceRNA hypothesis.

*6) In more general terms, we suggest that the Introduction should include a comprehensive review of all the papers in which the ceRNA-based relationship between* PTEN *and* PTENP1 *has been confirmed*:

*Poliseno, L., et al., Deletion of* PTENP1 *pseudogene in human melanoma. J Invest [Dermatol, 2011]{.ul}. 131(12): p. 2497-500*.

*Ioffe, Y.J., et al., Phosphatase and tensin homolog (*PTEN*) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis? Gynecol [Oncol, 2012]{.ul}. 124(2): p. 340-6*.

*Johnsson, P., et al., A pseudogene long-noncoding-RNA network regulates* PTEN *transcription and translation in human cells. Nat Struct Mol [Biol, 2013]{.ul}. 20(4): p. 440-6*.

*Yu, G., et al., Pseudogene* PTENP1 *functions as a competing endogenous RNA to suppress clear cell renal cell carcinoma progression. Mol Cancer [Ther, 2014]{.ul}*.

*Chen, C.L., et al., Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA* PTENP1 *and MicroRNA regulation. [Biomaterials, 2015]{.ul}. 44: p. 71-81*.

*Guo, X., et al., Pseudogene* PTENP1 *Suppresses Gastric Cancer Progression by Modulating* PTEN*. Anticancer Agents Med [Chem, 2015]{.ul}*.

We have included a more balanced discussion of the literature of the ceRNA hypothesis. In the Introduction, we try to focus on the experiments being replicated and any direct replications of them, instead of a comprehensive review of all the literature on this subject, which includes many conceptual or related experiments, which would be more appropriate for a review.

[^1]: 6 samples per group will be used based on the siLuc to 20a *PTEN* comparison making the power 99.9%.

[^2]: 6 samples per group will be used based on the siLuc to 20a *PTEN* comparison making the power 91.6%.

[^3]: 36 total samples (6 per group) will be used based on the planned comparisons making the power 99.9%.

[^4]: 6 samples per group will be used based on the siLuc to 20a *PTEN* comparison making the power 99.9%.

[^5]: 6 samples per group will be used based on the siLuc to 20a *PTEN* comparison making the power 93.4%.

[^6]: 6 samples per group will be used based on the siLuc to 20a *PTEN* comparison making the power 91.9%.

[^7]: 16 total samples (4 per group) will be used based on the planned comparisons making the power 99.9%.

[^8]: 16 total samples (4 per group) will be used based on the planned comparisons making the power 99.9%.

[^9]: 5 samples per group will be used based on the AUC calculation planned comparisons making the power 99.9%.

[^10]: 5 samples per group will be used based on the siLuc to siPTENP1 comparison making the power 99.9%.

[^11]: 5 samples per group will be used based on the siLuc to siPTENP1 comparison making the power 95.0%.

[^12]: 5 samples per group will be used based on the siLuc to siPTENP1 *PTEN* comparison making the power 99.8%.

[^13]: 5 samples per group will be used based on the siLuc to siPTENP1 *PTEN* comparison making the power 99.9%.

[^14]: 5 samples per group will be used based on the siLuc to siPTENP1 *PTEN* comparison making the power 99.3%.

[^15]: 40 total samples (5 per group) will be used based on the planned comparisons making the power 99.9%.

[^16]: 5 samples per group will be used based on the siLuc to siPTENP1 *PTEN* comparison making the power 99.9%.

[^17]: 5 samples per group will be used based on the siLuc to siPTENP1 *PTEN* comparison making the power 95.1%.

[^18]: 5 samples per group will be used based on the siLuc to siPTENP1 *PTEN* comparison making the power 99.9%.

[^19]: 5 samples per group will be used based on the siLuc to siPTENP1 *PTEN* comparison making the power 99.6%.

[^20]: 3 samples per group will be used based on the AUC calculation.
